Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance-Reference-Cited by-同舟云学术

Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance

Published:2015-10-01 Issue:6 Volume:98 Page:582-589
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Crona DJ¹,Milowsky MI²³,Whang YE²³

Affiliation:

1. Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy; University of North Carolina; Chapel Hill North Carolina USA

2. Division of Hematology and Oncology, Department of Medicine, School of Medicine; University of North Carolina; Chapel Hill North Carolina USA

3. Lineberger Comprehensive Cancer Center, University of North Carolina; Chapel Hill North Carolina USA

Funder

National Institute of General Medicine Sciences (NIGMS)

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference71 articles.

1. Cancer statistics, 2015. CA. Cancer;Siegel;J. Clin,2015

2. The current state of hormonal therapy for prostate cancer;Hellerstedt;CA. Cancer J. Clin,2002

3. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N. Engl. J. Med,2010

4. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;Bono;Lancet,2010

5. Alpha emitter radium-223 and survival in metastatic prostate cancer;Parker;N. Engl. J. Med,2013

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308;Oncology Reports;2024-08-07

2. Antitumor mechanisms and future clinical applications of the natural product triptolide;Cancer Cell International;2024-04-27

3. A new perspective on prostate cancer treatment: the interplay between cellular senescence and treatment resistance;Frontiers in Immunology;2024-04-17

4. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression;Journal of Medicinal Chemistry;2024-03-13

5. Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer;Scientific Reports;2023-10-04